Barrett's Esophagus: What Every GERD Patient Needs to Know
If you've had heartburn or acid reflux for years, you may have heard your doctor mention Barrett's esophagus — perhaps in passing, or as a reason for recommending an upper endoscopy. It's a term that understandably causes concern. Here is what Barrett's esophagus actually is, what it means for you, and what modern surveillance looks like.
What Is Barrett's Esophagus?
The esophagus is normally lined with flat, pale cells called squamous epithelium. In Barrett's esophagus, these cells are replaced by a different type of cell — intestinal-type columnar epithelium — in the lower esophagus, typically in response to years of acid exposure from GERD. This change is the body's attempt to protect the esophagus from acid, but it comes with a tradeoff: the new cells carry a higher risk of transforming into esophageal adenocarcinoma, a form of esophageal cancer.
How Common Is It?
Barrett's esophagus affects approximately 5–15% of patients with chronic GERD — though many people with Barrett's have no idea they have it. It is significantly more common in men, white individuals, adults over 50, and people with obesity, particularly central (abdominal) obesity. A family history of Barrett's or esophageal cancer also increases risk.
How Is Barrett's Esophagus Diagnosed?
Barrett's esophagus can only be diagnosed through upper endoscopy (EGD) with biopsy. During the endoscopy, the gastroenterologist can visually identify the characteristic salmon-colored tissue in the lower esophagus and take small biopsy samples that are sent to a pathologist for confirmation.
Many patients are surprised to learn they have Barrett's — because Barrett's itself causes no additional symptoms beyond the underlying GERD. The heartburn doesn't feel any different. This is why guidelines recommend consideration of upper endoscopy in patients with longstanding GERD, particularly men over 50 with obesity.
Barrett's Without Dysplasia vs. Barrett's With Dysplasia
Not all Barrett's esophagus carries the same risk. The key prognostic factor is whether dysplasia — precancerous cellular changes — is present in the biopsied tissue:
Barrett's without dysplasia: Low annual cancer risk (~0.1–0.3%). Managed with surveillance endoscopy every 3–5 years and acid suppression with a proton pump inhibitor.
Low-grade dysplasia (LGD): Higher cancer risk; surveillance every 6–12 months or endoscopic ablation therapy.
High-grade dysplasia (HGD): Significant cancer risk; endoscopic eradication therapy (radiofrequency ablation or endoscopic mucosal resection) is strongly recommended.
Does Having Barrett's Mean I'll Get Cancer?
No. The vast majority of patients with Barrett's esophagus never develop esophageal cancer. The annual risk of progression from Barrett's without dysplasia to cancer is approximately 0.1–0.3% per year — meaning most patients will live their entire lives with Barrett's and never develop cancer. The purpose of surveillance is to catch the minority who develop dysplasia or early cancer while it is still treatable.
Managing Barrett's Esophagus
Key components of management include: regular surveillance endoscopy at recommended intervals, optimization of acid suppression (usually a daily proton pump inhibitor), and endoscopic ablation for patients who develop dysplasia. Weight loss and smoking cessation are also recommended.
📅 Have longstanding GERD and haven't had an upper endoscopy? Book an evaluation at (908) 851-2770 or online.
Medical Disclaimer: This blog post is intended for general informational and educational purposes only and does not constitute medical advice.
